Filing Flows › Comparisons › MREO vs ARVN
Mereo BioPharma Group vs Arvinas: MREO and ARVN compared
Mereo BioPharma Group is the larger company: $500K of revenue in its latest quarter (Q2 2025) against $500K for Arvinas (Q3 2026).
Where the money goes: MREO and ARVN
Mereo BioPharma Group (MREO) · Q2 2025
Mereo BioPharma Group, Q2 2025: revenue $500K, net loss $14.6M, operating cash flow −$7.7M. The chart follows the revenue to costs, profit and cash.
Arvinas (ARVN) · Q3 2026
Arvinas, Q3 2026: revenue $500K (-99% year over year), net loss $53.9M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
| Mereo BioPharma Group (MREO) | Arvinas (ARVN) | |
|---|---|---|
| Latest quarter | Q2 2025 | Q3 2026 |
| Revenue | $500K | $500K |
| Revenue growth, Y/Y | — | -99% |
| Operating margin | n/m | n/m |
| Net earnings | −$14.6M | −$53.9M |
| Operating cash flow | −$7.7M | −$10.4M |
Questions
Which is bigger, Mereo BioPharma Group or Arvinas?
Mereo BioPharma Group is the larger company: $500K of revenue in its latest quarter (Q2 2025) against $500K for Arvinas (Q3 2026).
More: Mereo BioPharma Group earnings · how Mereo BioPharma Group makes money · Arvinas earnings · how Arvinas makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2025; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.